Moderna (NASDAQ:MRNA) reported quarterly losses of $(2.52) per share which beat the analyst consensus estimate of $(3.12) by 19.23 percent. This is a 17.92 percent increase over losses of $(3.07) per share from the same period last year. The company reported quarterly sales of $108.00 million which beat the analyst consensus estimate of $106.20 million by 1.70 percent. This is a 35.33 percent decrease over sales of $167.00 million the same period last year.